biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > The Biodexa Presentation for Roadshows

<< Previous

Bullboard Posts

Next >>

Comment by JDavenporton Dec 14, 2022 4:53pm

146 Views

Post# 35171852

RE:RE:The Biodexa Presentation for Roadshows

Rathjen is not worthless or imcompetent, Aarcor

She set this up in the dark.

She executed it in the dark with careful and minimal disclosures.

She'll make a lot of money from it.

I have lots of words to describe her but worthless and incompetent aren't at the top of the list.

About you predicting and characerizing a deal of this sort, you most certainly did not.

Don't bother claiming it.

If you ever hear Ladenburg Thalmann's name again, run, Forrest, run!

jd

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December